Laboratorios Richmond S.A.C.I.F. (BCBA:RICH)
Argentina · Delayed Price · Currency is ARS 1,735.00
+75.00 (4.52%)
Mar 23, 2026, 1:21 PM BRT
BCBA:RICH Income Statement
Financials in millions ARS. Fiscal year is January - December.
Millions ARS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 126,726 | 120,754 | 84,989 | 57,518 | 32,366 | |
Revenue Growth (YoY) | 4.95% | 42.08% | 47.76% | 77.71% | 246.90% |
Cost of Revenue | 48,273 | 54,952 | 40,233 | 30,340 | 22,765 |
Gross Profit | 78,452 | 65,802 | 44,757 | 27,178 | 9,602 |
Selling, General & Admin | 46,832 | 45,903 | 33,217 | 17,935 | 5,110 |
Other Operating Expenses | 1,714 | - | - | - | - |
Operating Expenses | 48,547 | 45,903 | 33,217 | 17,935 | 5,110 |
Operating Income | 29,906 | 19,899 | 11,539 | 9,243 | 4,492 |
Interest Expense | -14,967 | -9,012 | -18,718 | -4,456 | -1,451 |
Earnings From Equity Investments | -63.36 | -501.85 | -8.39 | 7.33 | - |
Currency Exchange Gain (Loss) | -13,054 | -11,485 | -55,069 | -9,159 | -1,783 |
Other Non Operating Income (Expenses) | 13,423 | 24,712 | 32,447 | 5,828 | 61.01 |
EBT Excluding Unusual Items | 15,245 | 23,612 | -29,808 | 1,462 | 1,319 |
Impairment of Goodwill | - | - | -523.72 | - | - |
Gain (Loss) on Sale of Investments | -6,911 | 13,984 | 10.26 | 1,019 | 1,436 |
Gain (Loss) on Sale of Assets | - | - | - | 8.19 | 6.46 |
Legal Settlements | -229.34 | - | - | - | - |
Pretax Income | 8,105 | 37,596 | -30,321 | 2,490 | 2,761 |
Income Tax Expense | 5,965 | 6,272 | -6,528 | 1,993 | 1,590 |
Earnings From Continuing Operations | 2,140 | 31,324 | -23,794 | 496.36 | 1,172 |
Earnings From Discontinued Operations | 683.72 | - | - | - | - |
Net Income to Company | 2,823 | 31,324 | -23,794 | 496.36 | 1,172 |
Minority Interest in Earnings | 264.58 | 44.33 | 164.53 | 12.58 | -19.42 |
Net Income | 3,088 | 31,368 | -23,629 | 508.94 | 1,152 |
Net Income to Common | 3,088 | 31,368 | -23,629 | 508.94 | 1,152 |
Net Income Growth | -90.16% | - | - | -55.83% | 56.98% |
Shares Outstanding (Basic) | 81 | 81 | 81 | 81 | 81 |
Shares Outstanding (Diluted) | 81 | 81 | 81 | 81 | 81 |
Shares Change (YoY) | -0.00% | 0.00% | -0.04% | 0.06% | -0.00% |
EPS (Basic) | 38.24 | 388.45 | -292.62 | 6.30 | 14.27 |
EPS (Diluted) | 38.24 | 388.45 | -292.62 | 6.30 | 14.27 |
EPS Growth | -90.16% | - | - | -55.85% | 56.99% |
Free Cash Flow | -35,921 | 1,181 | -25,022 | -34,174 | -3,045 |
Free Cash Flow Per Share | -444.85 | 14.63 | -309.87 | -423.02 | -37.71 |
Dividend Per Share | - | 26.890 | - | - | - |
Gross Margin | 61.91% | 54.49% | 52.66% | 47.25% | 29.67% |
Operating Margin | 23.60% | 16.48% | 13.58% | 16.07% | 13.88% |
Profit Margin | 2.44% | 25.98% | -27.80% | 0.89% | 3.56% |
Free Cash Flow Margin | -28.34% | 0.98% | -29.44% | -59.41% | -9.41% |
EBITDA | 32,999 | 29,469 | 16,621 | 11,522 | 5,165 |
EBITDA Margin | 26.04% | 24.40% | 19.56% | 20.03% | 15.96% |
D&A For EBITDA | 3,094 | 9,569 | 5,082 | 2,279 | 673.2 |
EBIT | 29,906 | 19,899 | 11,539 | 9,243 | 4,492 |
EBIT Margin | 23.60% | 16.48% | 13.58% | 16.07% | 13.88% |
Effective Tax Rate | 73.60% | 16.68% | - | 80.06% | 57.57% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.